Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy
|
|
|
- Monica Fisher
- 10 years ago
- Views:
Transcription
1 Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting Group 20 E. Market Street West Chester, Pennsylvania THE MARKET LEADER IN PHARMACEUTICAL CONSULTING
2 2 Developing a Supplier Policy as a Key Element of the Quality System that Assures Success Why do we need a Global Supplier Program and what are some key practical reasons for designing an effective system?
3 3 Developing a Supplier Policy as a Key Element of the Quality System that Assures Success In today s LEAN highly regulated and competitive world there s a new global expectation of pre-determined quality measures, more predictable mechanisms of delivery and measures to assure long-term sustainability of quality and product safety.
4 4 Points to Consider You want something that s meeting compliance requirements. You want something that provides value to the business. You want something that s cost effective to administer and maintain. The system MUST influence your supplier positively to assure they win and you win.
5 5 Some Design Drivers: It s mandated by the International Regulatory Requirements. It assures the suppliers operate their business to match your expectations and needs. It assures that material is always uniform, within specifications, manufactured to the highest quality standards and safe. It helps to mitigate risk. Streamlined LEAN systems make good business sense.
6 6 Regulations Involved with Supplier Management 21 CFR (b) FDA regards third party facilities as an extension of the manufacturer s own facility. 21 CFR The Quality Control Unit shall be responsible for approving or rejecting drug products manufactured, processed, packaged or held under contract by another company. 21 CFR Details the requirements for testing and approval/rejection of components for drug manufacturing.
7 7 Other Compliance Expectations ICH Q9 Risk Management Requires a detailed evaluation of suppliers and CMO s including auditing and implementing supplier quality agreements. The sponsor s Quality System should drive the management of outsourced activities. Members involved in the supply chain are viewed as partners in determining success.
8 8 Other Compliance Expectations ICH Q10 Quality Systems Sponsor responsibilities extend to the review of control of outsourced activities as an extension of their own Quality Management System. Sponsor should have adequate procedures for auditing and qualifying supplies prior to and during use in the supply chain activities.
9 9 Unacceptable Incidents In the absence of strong Supplier Management Systems the potential for failure is high: Heparin 81 deaths; 800+ adverse events Tainted Glycerin 300+ deaths TBA (2,4,6 Tribromoanisole) contamination Due to plastic bottles on wooden pallets treated at a contract CMO. Ritonavir Recall Pulled from market due to existence of a polymorph that decreased bioavailability of drug for HIV patients.
10 10 Developing a Strategy Using a lean compliance philosophy we can approach the development of an effective supplier policy around a Deming Cycle; Plan-Do-Check-Act. Continuously monitor and evaluate performance CHECK PLAN Plan and define the process Qualify the candidate ACT DO Carry out the selection process methodology
11 11 Important Tools in the Development of a Best Practice Global Sourcing Strategy Process Map of the Process Supplier Quality Questionnaire Effective Risk Management Strategy A Communications Infrastructure Audit Program Quality Agreements Metrics/Analytics Program Use of score cards
12 12 Supplier Sourcing Process Map Have a defined process map for your supplier process that s logical and considers cross-functional inputs. In developing this map understand the Current State as this will act as a reference point from which to develop the Best Practice Desired State. Transition to the Desired State as the strengths and weaknesses are understood. Desired State Current State
13 13 Supplier Questionnaire Tool Composition This can vary depending upon the complexity, but should always include quality, cost and performance factors. For Quality: Existence of GMP culture Adherence to GMP s and ICH guidelines Implementation of Quality System Existence of policies, SOPs and records Good Compliance Record No citations by regulatory authorities
14 14 Supplier Questionnaire Tool Composition For Process and Technological Capabilities: Appropriate facilities for production Capacity to deliver Strong technological capabilities Strong production controls Delivery performance record Clean environmental record
15 15 Supplier Questionnaire Tool Composition For Personnel and Management Capabilities: Strong understanding of key performance indicators for supply chain. Strong technical management controls. Strong project management expertise. No de-barred individuals by FDA or other authority Strong in-house acquisition policy to maintain supply capabilities Appropriate group chemistry and business culture fit to foster long-term cooperative relationship. Can-do spirit
16 16 Effective Risk Management Strategy Risk, what is it? Certainty and uncertainty The probability of something occurring The potential consequences of the result of something occurring Equipment breakdown Specification failure wasted batch Test failure lost productivity Certainty Uncertainty 80:20?
17 17 Effective Risk Management Strategy Risk Management is a knowledge management program providing Decision Makers the power to make better Quality decisions. It involves identifying potential failure causing issues. Ranking for criticality. Mitigating the effects of these. Where possible, eliminating these. Maintenance of sustainable compliance through oversight policy. Determine areas needed. Set out structure for levels required. Execute oversight measures. Review and make adjustments as necessary.
18 Risk Communication 18 Risk-based Approach Flow Chart Described in ICH Q9 Provides Direction Initiate Quality Risk Management Process Risk Assessment Risk Control Hazard Identification Risk Analysis Risk Evaluation Risk Reduction Risk Acceptance Output / Report and Implementation U N A C C E P T A B L E Risk Management Tools Risk Review Risk Event
19 19 Determine Criticality Through Quantitative/Qualitative Models Example: Compliance Record Historical Database of Compliance Issues Compliance Actions FDA violations requiring attention FDA objections voluntary action Periodic internal audit findings No issues Few issues Occasional issues Many issues Significant issues Low Medium High High High Low Low Medium High High Low Low Low Medium High
20 20 Determine Criticality Through Quantitative/Qualitative Models Now rank in terms of priority 1. GMP fault A 2. GMP fault X n. GMP fault N
21 21 Communications Infrastructure 4 issues: What, When, Whom and How What needs to be reported should be clearly defined based upon the degree of criticality When should something be reported? Immediately when it occurs In a monthly report Annually
22 22 Communications Infrastructure To Whom should things be reported QA Senior Management Procurement Specialist How should it be reported? Telephone Dashboard Written report
23 23 Audit Program Have a well defined audit plan and audit checklist to maintain consistency between vendors/suppliers and different auditors Define audit schedules/frequencies Define audit agendas Define reporting mechanism Define follow-up strategies
24 24 Quality Agreements Key Points Should delineate responsibilities and accountabilities for both the sponsor and the supplier Expectations Timelines Deliverables Should discuss change management issues Authority for changes Circumstances permitted
25 25 Quality Agreements Key Points Should define communications mechanisms and decision making process Should define mechanism for dispute resolution
26 26 Metrics / Analytics Program Set up an analytical program to continuously provide data for ongoing assessment. Gather data on each batch/lot received and use a dashboard to track performance Trend data and provide to Quality Review Board for assessment. Use analytics to separate poor performers from qualifiable candidates. Use analytics to provide useful data for supplier profiles Use audit data and data gathered for supplier questionnaire. Use data to continuously monitor performance and justify continued use. Use to establish Preferred Vendor list.
27 27 Example of Customer Scorecard Scores to ± 10 Score Attribute Ideal Score Example Score Documents received 1 0 Material quality OK 3 0 Delivery date Met 2 0 Material in good condition packaging 1 1 Quantity delivered 3 2 TOTAL 10 3 * This lot would receive a poor rating. Every delivery is scored.
28 28 Tips related to performing appropriate due diligence to develop best practices and assure success What to look for from Best in Class performers They: Have metrics/analytics and perform tracking of supplier performance Use real-time dashboards to monitor critical attributes and diminish supply chain disruptions Perform industry benchmarking to maintain standards Perform risk analytics to avoid/mitigate supplier related issues Leverage resources globally through standardized policies and practices to reduce duplication of effort or non-added value functions Influence outcomes through use of LEAN 6 Sigma to improve supplier performance
29 29 Tips related to performing appropriate due diligence to develop best practices and assure success Consolidate the housing of key supplier data through use of a central system Use single point of contact for streamlining of business and technical information/data. Demand > 80% on-time delivery of material or completion of tasks. Have fewer (< 2%) major failures. Use Risk Analysis to screen these suppliers out.
30 30 The role of the Quality audit as part of a supplier best practice and what to look for: Key points: They should be a central piece of a multi-factorial strategy to assure quality compliance readiness. They should be used in conjugation with questionnaire data gathering tools, Quality Agreements and Risk Analysis They can be targeted tools for evaluation of capacity capabilities or some specific compliance issue They can be used to assess compliance fit for the transition from clinical supply to full scale commercialized supply.
31 31 The role of the Quality audit as part of a supplier best practice and what to look for: What s important to you as a customer? Existence of policies that drive a Quality System Approach to the monitoring and control of supplies and their processes. Existence of systems that detect problems early and provide mechanisms to correct them and prevent future occurrences. Existence of Risk Analysis and mitigation processes as part of their management strategy
32 32 The role of the Quality audit as part of a supplier best practice and what to look for: What s important to you as a customer? The supplier s ability to meet your quality and technical specification requirements The supplier s ability to meet your capacity and delivery expectations Business fit and whether they are financially stable for long-term partnerships
33 33 Audit Reports Some important points: Detail what s working and what s not. Explain why failing suppliers don t meet the expectation of your qualification process. Detail remediation plans proposed to the supplier for qualification. Where there are inspection driven remediation activities, include a statement that the action being taken is acceptable to restore compliance.
34 34 Question Are full-scale mock audits required or can more focused audits be done? The issues are: Time: Dozens of audits can be time-prohibitive. Cost: for extensive audit program especially where overseas suppliers are involved, e.g., China. Risk: Possibility of missing something that s a key compliance factor Through a Risk Analysis and Mitigation Strategic mandated by ICH Q9, key points/problems can be addressed.
35 35 Solution Using a Risk Analysis approach then, one might advocate targeted audits on a specific supplier process that might critically impact your process. Examples might include: A thorough review of technical critical issues associated with the manufacturing of a Purification Resin that s a key component of your process. Rather than looking at their training program and/or facility issues. Focus on the validation of a test method used to release your product. Rather than their own supplier policy.
36 36 What can be learned from analyzing historical trends? Lessons learned related to capacity and capabilities. Ranking of issues based upon field experiences in last 3 years. Issue affecting performance Ranking Manufacturing errors due to personnel actions #1 Errors due to documentation mistakes, data, incomplete reviews #2 Product contaminations or specification failures #3 Equipment breakdowns causing lost materials #4 Delays due to silo practices #5
37 37 Historical Trends for Capabilities Performance of Suppliers Capabilities Subset of Suppliers Top 25% Middle 50% Bottom 25% > 90% on-time delivery of supplies. Includes: Finished goods Components Raw materials API 75% on-time delivery of supplies X < 50% on-time delivery of supplies X X Failure rates in production < 2% 5% > 5%
38 38 What are common QC / QA issues experienced and how can they be ameliorated? Recommendation: Always develop a strategy to determine Root Cause Ask 5 Why s; Why did that occur? Perform Fishbone or Ishikawa Exercise Materials Methods Machines Problem Measurements Environment People T I M E
39 39 What are common QC/QA issues experienced and how can they be ameliorated? Example 1 Issue Changes made without notification that might affect product quality. Case of the laboratory method change; Contract laboratory changes method used for test involved in product release. Solution Better communication between testing laboratory and client company Enforcement of issues in the Quality Agreement by the host Procurement and QA group.
40 40 What are common QC/QA issues experienced and how can they be ameliorated? Example 2 Issue Incomplete laboratory investigations due to large number of incidents generated. Caused bottleneck and delays in release of API Solution Assessment identified change in method of analysis from HPLC to UPLC resulted in better use of resources and reduced incidence of errors.
41 41 What are common QC/QA issues experienced and how can they be ameliorated? Example 3 Issue CAPA Programs that are either not followed through on or don t reach root cause remediation. Solution Training on root cause analysis together with the implementation of a follow-up policy for close-out of remediation measures.
42 42 What can be learned from recent FDA warning letters and activity? ~ 20% of the warning letters in the last 2 years related to manufacturing quality related to supplier controls. Supplier management contributes to a Cost of Quality that s 6x greater than that of other manufacturing industries like semi-conductor and automotive.
43 43 What can be learned from recent FDA warning letters and activity? Three major factors contribute to this: The cost and availability of resources. Use or non-uniform and inefficient processes. The changing regulatory and commercial environment. Why? Supplier management is expanding as the numbers enlarge and the oversight needed increases. As expectations in regulatory content evolve, tighter controls frequently require more resources to implement. As market competition changes, unless growth is sustained, there s pressure to reduce operating costs. Resources are being disproportionately deployed on issues that may require less attention due to lower criticality.
44 44 What can be learned from recent FDA warning letters and activity? Some important points: As more and more focus in put on Asian suppliers, regulators perceive this puts more strain on maintaining compliant supply chains. The result is this is catching their attention. Implementation of Risk Management Strategies is occurring more on a product by product basis.
45 45 Supplier Management Programs; Some Trends The quality of the Supplier Management Process is inadequate. Examples Your vendor qualification has not provided adequate evidence that the manufacturer can consistently supply raw materials. Your API suppliers are not monitored and regularly scrutinized to ensure ongoing reliability. You did not specify how you intend to document and implement supplier audits. Your firm has not conducted at least one specific identity test and has not established the reliability of the suppliers analysis through appropriate validation of the supplies test results at suitable intervals.
46 46 Supplier Management Programs; Some Trends Certificates of Analysis Your firm accepts supplier Certificates of Analysis without having qualified the vendor. You failed to validate your supplier test results supplied to you on the Certificate of Analysis. You receive a Certificate of Analysis with the components and discard it without conducting any review.
47 47 Some other important points related to supplier management from recent FDA interactions FDA has concerns over the concept of supplier authority. Did the person signing the Quality Agreement have authority to commit to the terms? When suppliers support a virtual or blended company structure assure that they are supported by adequate management controls at your company. Plan what documentation you require to verify regulatory compliance so as to mitigate your Risk Exposure. Assure your document retention policy meets prevailing expectations for the global harmonized regulatory agencies.
48 48 Some other important points related to supplier management from recent FDA interactions FDA is communicating that where outsourced CMO/CRO vendors are used, in addition to supplier selection, evaluation and qualification processes the following points will receive attention for oversight: Ongoing assessment of results Issues connected with change management and supplier controls Ongoing Risk Assessment and Mitigation Processes
49 49 Some other important points related to supplier management from recent FDA interactions Onsite receipt of materials from suppliers and associated processes. Handling of third party CAPA processes. Follow-up remediation action from noted audit deficiencies.
50 50 Concluding Thoughts Effective Supplier Management in a global environment requires partnership and cooperation at multiple levels as well as cross-functionality. Use of the correct tools integrated with strong policies will provide a basis for a successful outcome. However, it s important to keep it LEAN and simple!
51 51 Questions? Thank you for this opportunity to share our ideas with you. For more information, visit: Or
Aligning Quality Management Processes to Compliance Goals
Aligning Quality Management Processes to Compliance Goals MetricStream.com Smart Consulting Group Joint Webinar February 23 rd 2012 Nigel J. Smart, Ph.D. Smart Consulting Group 20 E. Market Street West
Auditing as a Component of a Pharmaceutical Quality System
Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a
Best Practice In A Change Management System
Quality & Compliance Associates, LLC Best Practice In A Change Management System President Quality & Compliance Associates, LLC Change Control and Its Role in a Continuous Improvement Environment 3 Benefits
Addressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014
Addressing Risk in Partner / Contractor Selection and Onboarding Michael Davidson VP Quality Systems and Compliance March 2014 Industry Trends Pfizer Overview Pfizer s Approach Risk Based Robust Due Diligence
Camber Quality Assurance (QA) Approach
Camber Quality Assurance (QA) Approach Camber s QA approach brings a tested, systematic methodology, ensuring that our customers receive the highest quality products and services, delivered via efficient
How CMOs are Turning Their Training Programs into Market Differentiators
How CMOs are Turning Their Training Programs into Market Differentiators How CMOs are Turning Their Training Programs into Market Differentiators A Contract Manufacturing Organization (CMO) has as much
Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions
WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing
Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.
Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management
Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants
Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants Alex D. Kanarek, PhD BioProcess Technology Consultants, Inc. Strategic Institute Quality
Empowering the Quality and Regulatory Compliance Functions
Empowering the Quality and Regulatory Compliance Functions Management must take steps to ensure that regulatory and quality compliance is everyone s responsibility. By: J. Glenn George, Kenneth Imler,
Guidance for Industry. Q10 Pharmaceutical Quality System
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
UNICEF s Quality Assurance System for Procurement of Micronutrient Powders (MNP)
UNICEF s Quality Assurance System for Procurement of Micronutrient Powders (MNP) Nutrition Supplier Meeting, June 30, 2015 Dimitris Catsoulacos Quality Assurance Specialist PRESENTATION OVERVIEW Quality
Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
Supply Chain Challenges and Risk Management
Supply Chain Challenges and Risk Management Presented by Steve Williams Director SeerPharma P/L 21 st April 2009 PDA April 09 SW 1 Supply Chain - Some Useful Guidance cgmp Annex 8 cgmp Chapter 7 ICH Q7
Product Lifecycle Management in the Medical Device Industry. An Oracle White Paper Updated January 2008
Product Lifecycle Management in the Medical Device Industry An Oracle White Paper Updated January 2008 Product Lifecycle Management in the Medical Device Industry PLM technology ensures FDA compliance
Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations
Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical
Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
PHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
Guidance for Industry: Starting Material Supplier Management
Guidance for Industry: Starting Material Supplier Management Version 1.0 Drug Office Department of Health. Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. Selecting and
Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA
Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA This presentation is the property of DynPort Vaccine Company LLC, a CSC company, and
Establish Collaborative Strategies to Better Manage a Global Vendor Network Devise a Proper Float Plan
Establish Collaborative Strategies to Better Manage a Global Vendor Network Devise a Proper Float Plan CBI s Biopharmaceutical Forum on Clinical and Commercial Global Supply Chain Excellence Sandy Onorato
Corrective and Preventive Actions
Corrective and Preventive Actions A Five Step Approach Topics to Be Covered What is CAPA? Governing authority Five steps to a good CAPA process Where companies have difficulty Example citations Recap What
The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.
Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations
Making Improvement Work in Pharmaceutical Manufacturing Some Case Studies. Ronald D. Snee
Making Improvement Work in Pharmaceutical Manufacturing Some Case Studies Ronald D. Snee ISPE Midwest Extended Education and Vendor Day Overland Park, KS 2 May 2007 King of Prussia PA New York NY Washington
Pharmaceutical Quality Systems: US Perspective
Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical
GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations
GxP Process Management Software : Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations Most FDA violations involve one of the following: Not having procedures in a regulated area
Regulatory Asset Management: Harmonizing Calibration, Maintenance & Validation Systems
Regulatory Asset Management: Harmonizing Calibration, Maintenance & Validation Systems 800.982.2388 1 Introduction Calibration, maintenance and validation activity, despite operating within the same department
Library Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
GMP Pharma BV. Netherlands
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme
GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme Contents 1. Why good documentation is essential? 2. What constitutes
Building an Effective Supplier Control Program: A review of key program elements & their implementation.
Building an Effective Supplier Control Program: A review of key program elements & their implementation. Jonathan Lee VP RQCS Medtronic Surgical Technologies Building an Effective Supplier Control Program
ICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010
ICH Q 10 Pharmaceutical Quality System PQS DIA China Annual Meeting, May 2010 Joseph C. Famulare Head of External Relations and Collaboration Pharma Global Technical Operations Global Quality, F. Hoffmann-La
Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations
Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
Author General Management Quality Assurance
Lab Ofichem B.V. Pag.: 1 / 14 Date: 20-01- Version: 02 Status: geldig Contents 1. General... 2 2. Shared Third Party audit program... 3 3. Reassurance absence of Conflict of Interest... 5 4. Contract structure...
TrackWise - Quality Management System
TrackWise - Quality Management System Focus area: Electronic Management of CAPA Systems in the Regulated Industry May 11, 2007 Yaniv Vardi VP, Operations Sparta Systems Europe, Ltd. Agenda Sparta Systems
Corrective and Preventive Action Background & Examples Presented by:
Corrective and Preventive Action Background & Examples Presented by: Kimberly Lewandowski-Walker Food and Drug Administration Division of Domestic Field Investigations Office of Regulatory Affairs Overview
Compliance Control Procedure Execution Management System Reduces Compliance Risks by 10X
Compliance Control Procedure Execution Management System Reduces Compliance Risks by 10X By John Helfrich, VelQuest Corporation INTRODUCTION The top drug GMP violations in 2009 involved failings in manufacturers'
Application of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations
Application of Quality Risk Management to Pharmaceutical Operations Eldon Henson, Vice President, Quality Operations Key Topics of Discussion Definition of Quality Risk Management (QRM) Overview of PDA
Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers
Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers integrating GMP (ICH Q7a) into ISO (9001: 2000) September 2005 Quality Management System - integrating GMP (ICH
ICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
Workshop on Quality Risk Management Making Trials Fit for Purpose
Clinical Trials Transformation Initiative Workshop on Quality Risk Management Making Trials Fit for Purpose Andy Lee SVP, Global Clinical Operations, Genzyme Corporation August 23/24, 2011 Hyatt Regency,
AssurX Makes Quality & Compliance a Given Not Just a Goal
AssurX Makes Quality & Compliance a Given Not Just a Goal TRACK. MANAGE. AUTOMATE. IMPROVE. AssurX s powerfully flexible software unites and coordinates information, activities and documentation in one
Four Best Practices To Improve Quality In The Supply Chain. Lower your supply chain risks and cost of quality
Four Best Practices To Improve Quality In The Supply Chain Lower your supply chain risks and cost of quality 1Introduction 2Quality Risks in the Supply Chain 3 Best Practices to improve quality in the
Purchase Order Management
RESEARCH BRIEF APRIL 2014 Improving Order and Fulfillment Operations: Purchase Order Management Sponsored by: Research conducted by: On behalf of: Introduction The growth of global supply chain has put
Standardizing Best Industry Practices
MEDICAL DEVICES Current market conditions have created a highly competitive and challenging environment for the medical device industry. With stricter FDA regulatory oversight, increasing material costs
IFS Food Safety and Quality Management System
This is an ideal package for Food Manufacturers looking to meet the requirements of the IFS Food Standard for quality and food safety of food products. Ensure your Food Safety & Quality Management System
Business Continuity Position Description
Position Description February 9, 2015 Position Description February 9, 2015 Page i Table of Contents General Characteristics... 2 Career Path... 3 Explanation of Proficiency Level Definitions... 8 Summary
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE
ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE THIS POLICY OUTLINES THE TOP LEVEL REQUIREMENTS TO SUPPORT PRODUCT QUALITY IN THE DEVELOPMENT, MANUFACTURE AND DISTRIBUTION OF ACTIVE PHARMACEUTICAL
Top Seven Risks to Consider When Selecting a Life Science LMS
Top Seven s to Consider When Selecting a Life Science LMS THE UNINTENDED CONSEQUENCES OF UNINFORMED DECISIONS IN THIS PAPER: Identifying and avoiding gaps in LMS functionality that may lead to critical
Preparing for an FDA Pre-Approval Inspection (PAI)
Preparing for an FDA Pre-Approval Inspection (PAI) Jorge Torres CMQ/OE, CQE, CQA July, 2007 1 Agenda Introduction Understanding the PAI Experience: What to Expect Inspection Management Plan Preparing for
Annex 2. WHO guidelines on quality risk management. 1. Introduction 62. 2. Glossary 67 3. Quality risk management process 70
Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating
Information Technology Project Oversight Framework
i This Page Intentionally Left Blank i Table of Contents SECTION 1: INTRODUCTION AND OVERVIEW...1 SECTION 2: PROJECT CLASSIFICATION FOR OVERSIGHT...7 SECTION 3: DEPARTMENT PROJECT MANAGEMENT REQUIREMENTS...11
Pharmaceutical Wholesaler Site Inspection Checklist
Pharmaceutical Wholesaler Site Inspection Checklist Date and time of inspection: Legal business name and plant name: Location (address): Phone number: Fax number: Email address: Web site URL: Contact Person:
Audits must be conducted with due concern for employee safety and environmental protection.
Standard Operating Procedure Title: GMP Audit Procedure Related Documents TEM-080 Internal Audit Report Template TEM-120 Vendor Audit Report Template Form-385 Vendor Audit Questionnaire Form-445 EHS Workplace
Shared Assessments Program Case Study
Shared Assessments Program Case Study A Collaborative Approach to Onsite Assessments Using the Shared Assessments AUP, the Standardized Testing Procedures for Onsite Assessments April 2015 Background About
QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH
QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH Martin Valania, Executive Director, Corporate QA and Compliance Introduction Pharmaceutical companies recognize the benefits of carefully managing
Standard of measurement by which efficiency, performance, progress, or quality of a plan, process, or product can be assessed 1.
Meaningful Metrics What is a Metric? Standard of measurement by which efficiency, performance, progress, or quality of a plan, process, or product can be assessed 1. A quality metric is a measurement of
MANAGING THE COMPLEXITIES OF GLOBAL PHARMACEUTICAL SOURCING
DPT Thought Leadership Issue 10 MANAGING THE COMPLEXITIES OF GLOBAL PHARMACEUTICAL SOURCING With the increased globalization and complexity of the pharmaceutical supply chain, managing the sourcing of
Harmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
Computer-Aided Facilities Management - A Logical Trend
Computer-Aided Facilities Management - A Logical Trend Two major organisational changes are part of the modern pharmaceutical industry scene. Firstly, mergers as companies seek to consolidate resources
Domain 1 The Process of Auditing Information Systems
Certified Information Systems Auditor (CISA ) Certification Course Description Our 5-day ISACA Certified Information Systems Auditor (CISA) training course equips information professionals with the knowledge
Quality Management System General
Audit Date: Quality Management System General Requirement: 4.1 and 4.2.2-QMS General Verify Scope Comments/Evidence/Findings: Verify the Exclusions is applicable and justified How are the processes in
Simply Sophisticated. Information Security and Compliance
Simply Sophisticated Information Security and Compliance Simple Sophistication Welcome to Your New Strategic Advantage As technology evolves at an accelerating rate, risk-based information security concerns
Big Data / FDAAWARE. Rafi Maslaton President, cresults the maker of Smart-QC/QA/QD & FDAAWARE 30-SEP-2015
Big Data / FDAAWARE Rafi Maslaton President, cresults the maker of Smart-QC/QA/QD & FDAAWARE 30-SEP-2015 1 Agenda BIG DATA What is Big Data? Characteristics of Big Data Where it is being used? FDAAWARE
AS9100 Quality Manual
Origination Date: August 14, 2009 Document Identifier: Quality Manual Revision Date: 8/5/2015 Revision Level: Q AS 9100 UNCONTROLLED IF PRINTED Page 1 of 17 1 Scope Advanced Companies (Advanced) has established
WHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE
WHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE White paper produced by Maetrics For more information, please contact global sales +1 610 458 9312 +1 877 623 8742 [email protected]
A Model for Training/Qualification Record Validation within the Talent Management System
A Model for Training/Qualification Record Validation within the Talent Management System IN THIS PAPER: Meeting 21 CFR Part 11 and Annex 11 Requirements Delivering Qualification Transcripts During Audits
ORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP 9 Golder Ranch Rd., Ste. 1 Tucson, Arizona 9 Web Site: E-mail: 20-2-0 20-2-0 (FAX) CONSULTING MEMORANDUM QUALITY SYSTEM INSPECTION TECHNIQUE
PHASE 8: IMPLEMENTATION PHASE
PHASE 8: IMPLEMENTATION PHASE The Implementation Phase has one key activity: deploying the new system in its target environment. Supporting actions include training end-users and preparing to turn the
How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters
environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing
GUIDANCE FOR MANAGING THIRD-PARTY RISK
GUIDANCE FOR MANAGING THIRD-PARTY RISK Introduction An institution s board of directors and senior management are ultimately responsible for managing activities conducted through third-party relationships,
Strategic Meetings Management Program (SMMP) Implementation and Idea Guide
Title Page Strategic Meetings Management Program (SMMP) Implementation and Idea Guide By Corbin Ball Associates This report was commissioned by SignUp4 (www.signup4.com). Index Strategic Meetings Management
Using Training Data to Drive Up Quality Metrics SURVEY OF QUALITY ASSURANCE EXECUTIVES
Using Training Data to Drive Up Quality Metrics SURVEY OF QUALITY ASSURANCE EXECUTIVES SURVEY OF QUALITY ASSURANCE EXECUTIVES The FDA s Push for Data and Metrics For the US FDA investigator, the single
CATSA Screening Contractor Management System Standard (2015)
Public Works and Government Services Canada Canadian General Standards Board Travaux publics et Services gouvernementaux Canada Office des normes générales du Canada CATSA Screening Contractor Management
1 www.imarcresearch.com
Risk Management in Clinical Research: PROCESS DEVELOPMENT & APPLICATION Introduction Recently, two key pieces of guidance were released from Food and Drug Administration (FDA) and European Medicines Agency
Lean Process Improvements for the GMP Laboratory
Lean Process Improvements for the GMP Laboratory ITRODUCTIO Pharmaceutical manufacturing costs the industry approximately $90 billion each year and represents twice the expenditure of research and development.
Adopting Site Quality Management to Optimize Risk-Based Monitoring
Adopting Site Quality Management to Optimize Risk-Based Monitoring Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective
INTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to
INTRODUCTION This book offers a systematic, ten-step approach, from the decision to validate to the assessment of the validation outcome, for validating configurable off-the-shelf (COTS) computer software
OPTIMUS SBR. Optimizing Results with Business Intelligence Governance CHOICE TOOLS. PRECISION AIM. BOLD ATTITUDE.
OPTIMUS SBR CHOICE TOOLS. PRECISION AIM. BOLD ATTITUDE. Optimizing Results with Business Intelligence Governance This paper investigates the importance of establishing a robust Business Intelligence (BI)
ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE (APIC) SUPPLIER QUALIFICATION & MANAGEMENT GUIDELINE
ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE (APIC) SUPPLIER QUALIFICATION & MANAGEMENT GUIDELINE December 2009 Content 1. Introduction 2. Chapter 1: Supplier Selection 3. Chapter 2: Due Diligence 4. Chapter
Implementing New USP Chapters for Analytical Method Validation
Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: [email protected] Today s Agenda Handling Method Changes vs. Adjustments
Regulation and Risk Management of Combination Products
Regulation and Risk Management of Combination Products Katherine Ulman Associate Scientist Global Regulatory Compliance Manager Dow Corning Healthcare Jim Curtis Senior Specialist, Healthcare Applications
White paper. Corrective action: The closed-loop system
White paper Corrective action: The closed-loop system Contents Summary How corrective action works The steps 1 - Identify non-conformities - Opening a corrective action 6 - Responding to a corrective action
www.pwc.com Third Party Risk Management 12 April 2012
www.pwc.com Third Party Risk Management 12 April 2012 Agenda 1. Introductions 2. Drivers of Increased Focus on Third Parties 3. Governance 4. Third Party Risks and Scope 5. Third Party Risk Profiling 6.
Final Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed by the ICH SC on 10 November 2005
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Final Business Plan Q10: Pharmaceutical Quality Systems dated 14 October 2005 Endorsed
HITRUST CSF Assurance Program
HITRUST CSF Assurance Program Simplifying the information protection of healthcare data 1 May 2015 2015 HITRUST LLC, Frisco, TX. All Rights Reserved Table of Contents Background CSF Assurance Program Overview
MeriCal Quality Profile
January 5, 2015 Dear Valued Customer, Since the implementation of new federal regulations, MeriCal Inc. has received a large volume of questionnaires and surveys regarding our services and procedures.
Lean Six Sigma Training The DMAIC Story. Unit 6: Glossary Page 6-1
Unit 6: Glossary Page 6-1 Glossary of Terms Unit 6: Glossary Page 6-2 Action Plan A technique that documents everything that must be done to ensure effective implementation of a countermeasure or improvement
The Power of Risk, Compliance & Security Management in SAP S/4HANA
The Power of Risk, Compliance & Security Management in SAP S/4HANA OUR AGENDA Key Learnings Observations on Risk & Compliance Management Current State Current Challenges The SAP GRC and Security Solution
Hazard Analysis and Critical Control Points (HACCP) 1 Overview
Manufacturing Technology Committee Risk Management Working Group Risk Management Training Guides Hazard Analysis and Critical Control Points (HACCP) 1 Overview Hazard Analysis and Critical Control Point
PHARMACEUTICAL OUTSOURCING:
PHARMACEUTICAL OUTSOURCING: QUALITY MANAGEMENT AND PROJECT DELIVERY Trevor Deeks, Karen Ginsbury and Susan Schniepp Editors CONTENTS Preface 1 OVERVIEW OF OUTSOURCED OPERATIONS Susan Schniepp 2 LEGAL ASPECTS
Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products
Guidance for Industry Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products U.S. Department of Health and Human Services Food and Drug Administration
Software Development for Medical Devices
Software Development for Medical Devices Overcoming the Challenges of Compliance, Quality and Cost Software is fast becoming the differentiator for manufacturers of medical devices. The rewards of software
Software Development for Medical Devices
Overcoming the Challenges of Compliance, Quality and Cost An MKS White Paper Introduction Software is fast becoming the differentiator for manufacturers of medical devices. The rewards available from software
